Dear TSITC Members and Esteemed Colleagues,
Time flies, this year marks the 8th anniversary of the Taiwan Society for Immunotherapy of Cancer (TSITC). Since our founding in 2017, we have witnessed remarkable advancements in cancer immunotherapy. Many patients who once had limited treatment options now have renewed hope, thanks to scientific breakthroughs. Driven by a shared sense of mission and responsibility, we continue working to extend the benefits of immunotherapy to more patients in need.
The establishment of TSITC was no easy task. We are deeply grateful to our Founding President, Professor Wen-Chen Chang, as well as all past and current board members and committee teams for their dedication and contributions. Over the years, TSITC has become a vital platform in Taiwan for collaboration in cancer immunotherapy — bringing together physicians, pharmacists, nurses, researchers, and the biotech industry. It is a great honor for me to carry this responsibility forward, and I remain committed to our founding vision, building on the efforts of those who came before us.
Looking ahead, we are entering a new era of cancer treatment. Innovations such as immunotherapy, targeted therapies, genetic testing, and cell-based treatments are rapidly evolving, offering patients more options and renewed hope. However, these advancements also come with challenges: ensuring safety and efficacy, minimizing side effects, and expanding access so that more patients can benefit from cutting-edge therapies. These are the critical issues we must tackle together.
To further TSITC's impact and benefit more patients, we will focus on the following key directions:
-
Advancing Academic Exchange and Clinical Application
We will continue to host high-quality scientific conferences, training programs, and international collaborations to keep our members informed of the latest developments in immunotherapy and ensure safer, more effective clinical application.
-
Promoting Cross-Disciplinary Collaboration
Cancer care is a team effort. We aim to strengthen collaboration across disciplines — uniting physicians, pharmacists, nurses, researchers, and patient advocacy groups—to develop more precise, patient-centered treatment strategies.
-
Enhancing Patient Education and Public Advocacy
Beyond professional practice, we are committed to addressing patients’ needs. Through accessible educational activities, we will help patients and families better understand immunotherapy. We will also actively engage in policy advocacy to promote a more supportive healthcare environment and ensure that innovative treatments reach those who need them most.
-
Strengthening Global Partnerships
We will deepen our collaboration with key international organizations, such as the Society for Immunotherapy of Cancer (SITC), to elevate Taiwan’s presence on the global stage and share our clinical and research achievements in cancer immunotherapy.
Our mission has remained unwavering since day one. I sincerely thank every board member, committee volunteer, Secretariat staff, and supporting member who has contributed to TSITC's growth. The road ahead will still require our collective effort. Together, let us continue advancing cancer treatment and bringing hope to more patients.
Here's to the next milestone, thank you all!
